tradingkey.logo
tradingkey.logo

Eli Lilly Says Taltz And Zepbound Met Primary And All Key Secondary Endpoints For Statistical Superiority To Taltz Monotherapy At 36 Weeks

ReutersMar 28, 2026 7:26 PM

- Eli Lilly and Co LLY.N:

  • PHASE 3B DATA PRESENTED AT AAD ANNUAL MEETING SHOW LILLY'S TALTZ (IXEKIZUMAB) PLUS ZEPBOUND (TIRZEPATIDE) DELIVERED SUPERIOR EFFICACY FOR ADULTS WITH PSORIATIC ARTHRITIS AND OBESITY

  • ELI LILLY - TALTZ AND ZEPBOUND MET PRIMARY AND ALL KEY SECONDARY ENDPOINTS FOR STATISTICAL SUPERIORITY TO TALTZ MONOTHERAPY AT 36 WEEKS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI